**If you are eligible and happy to participate in this survey please click 'Next' to continue*.***

End of Block: Explanatory Statement and Consent

Start of Block: Demographics

Q2 Demographics

* General Practitioner (1)
* Registrar (2)

Q3 Years of Practice:

* (1)
* 1-10 years (2)
* 11-20 years (3)
* >20 years (4)

Q5 What is the geographical location where you practice most in Gippsland?

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q4 **If you practice in more than one location, please complete this survey for the practice you spend most of your time.**  
   
 Do you or your practice have a guideline in place for skin cancer follow-up?

* Yes (1)
* No (2)

Skip To: End of Block If If you practice in more than one location, please complete this survey for the practice you spend most of your time. Do you or your practice have a guideline in place for skin cancer follow-up? = No

Q7 What kind of skin cancer follow-up guidelines do you use most?

* Personal (1)
* Practice (2)
* National (3)
* Other. Please specify: (4) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q8 How familiar are you with using your skin cancer follow-up guidelines?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Not at all (1) | Use it seldomly (2) | Use it occasionally (3) | Use it confidently and often (4) | Very familiar and use all the time (5) |
| (1) |  |  |  |  |  |

End of Block: Demographics

Start of Block: Information about Follow-up guidelines

Q9 How do you determine the frequency of follow-up for the majority of Basal Cell Carcinoma (BCC) skin cancer patients?

* Opportunistic follow-up (1)
* Scheduled follow-up specific for BCC (2)
* Only when the patient requests follow-up (3)
* Other. Please specify: (4) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q11 How do you determine the frequency of follow-up for the majority of Squamous Cell Carcinoma (SCC) skin cancer patients?

* Opportunistic follow-up (1)
* Scheduled follow-up specific for SCC (2)
* Only when the patient requests follow-up (3)
* Other. Please specify: (4) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q12 How do you determine the frequency of follow-up for the majority of melanoma skin cancer patients?

* Opportunistic follow-up (1)
* Scheduled follow-up specific for melanoma (2)
* Only when the patient requests follow-up (3)
* Other. Please specify: (4) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q10 How long is your follow-up?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 3 years (1) | 5 years (2) | Lifelong (3) | Other (4) |
| BCC (1) |  |  |  |  |
| SCC (2) |  |  |  |  |
| Melanoma (3) |  |  |  |  |

Q13 If you answered 'Other' above, please specify the length of follow-up:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

End of Block: Information about Follow-up guidelines

Start of Block: Information on Recall System

Q14 Do you have a recall system for skin cancer follow-up at your practice?

* Yes (1)
* No (2)

Skip To: End of Block If Do you have a recall system for skin cancer follow-up at your practice? = No

Q15 How do you contact/recall patients for skin cancer follow-up? Please choose all options that are relevant.

* Post / Mail (1)
* Phone call (2)
* SMS / Text message (3)
* Email (4)
* Other. Please specify: (5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q16 Who coordinates the skin cancer follow-up process?

* Doctor-initiated (1)
* Nurse-initiated (2)
* Reception-initiated (3)
* Other. Please specify: (4) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

End of Block: Information on Recall System

Start of Block: Information on skin cancers and follow-up in practice

Q17 What do the majority of follow-up examinations for skin cancer involve? Please choose all options that are relevant.

* Whole body skin check (1)
* Review of scar / operating site for recurrence (2)
* Examination of relevant lymph nodes (3)
* Imaging modalities - e.g. Ultrasound of liver, CT scan, Chest x-ray (4)
* Other. Please explain: (5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q18 What is your average number of skin cancer consultations per week (including suspicious of skin cancer, new skin lesions and skin cancer follow-up)?

* (1)
* 5-9 (2)
* 10-14 (3)
* 15 or more (4)

Q19 Of the skin cancers you have managed, what is the estimated percentage of shared care follow-up with specialists?

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 |

|  |  |
| --- | --- |
| BCC () |  |
| SCC () |  |
| Melanoma () |  |

Q20 What are the biggest challenges for rural GPs in managing skin cancer follow-up?

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q21 Do you have any suggestions on improving skin cancer follow-up from a GP perspective?

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

End of Block: Information on skin cancers and follow-up in practice